In silico identified targeted inhibitors of P‐glycoprotein overcome multidrug resistance in human cancer cells in culture
Open Access
- 10 August 2015
- journal article
- research article
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 3 (5) , e00170
Abstract
Failure of cancer chemotherapies is often linked to the over expression of ABC efflux transporters like the multidrug resistance P‐glycoprotein (P‐gp). P‐gp expression in cells leads to the elimination of a variety of chemically unrelated, mostly cytotoxic compounds. Administration of chemotherapeutics during therapy frequently selects for cells that over express P‐gp and are therefore capable of robustly exporting diverse compounds, including chemotherapeutics, from the cells. P‐gp thus confers multidrug resistance to a majority of drugs currently available for the treatment of cancers and diseases like HIV/AIDS. The search for P‐gp inhibitors for use as co‐therapeutics to combat multidrug resistances has had little success to date. In a previous study (Brewer et al., Mol Pharmacol 86: 716–726, 2014), we described how ultrahigh throughput computational searches led to the identification of four drug‐like molecules that specifically interfere with the energy harvesting steps of substrate transport and inhibit P‐gp catalyzed ATP hydrolysis in vitro. In the present study, we demonstrate that three of these compounds reversed P‐gp‐mediated multidrug resistance of cultured prostate cancer cells to restore sensitivity comparable to naïve prostate cancer cells to the chemotherapeutic drug, paclitaxel. Potentiation concentrations of the inhibitors were μmol/L. The inhibitors did not exhibit significant toxicity to noncancerous cells at concentrations where they reversed multidrug resistance in cancerous cells. Our results indicate that these compounds with novel mechanisms of P‐gp inhibition are excellent leads for the development of co‐therapeutics for the treatment of multidrug resistances.Keywords
Funding Information
- National Institute of General Medical Sciences National Institutes of Health (NIH/NIGMS) (1R15GM094771 - 01A1)
- SMU University Research Council
- SMU Dedman College Dean's Research Council
- Dedman College Center for Drug Discovery, Design and Delivery (CD4)
- Communities Foundation of Texas, Dallas
This publication has 57 references indexed in Scilit:
- Multiple Transport-Active Binding Sites Are Available for a Single Substrate on Human P-Glycoprotein (ABCB1)PLOS ONE, 2013
- P-glycoprotein Retains Drug-stimulated ATPase Activity upon Covalent Linkage of the Two Nucleotide Binding Domains at Their C-terminal EndsJournal of Biological Chemistry, 2011
- The “Specific” P-Glycoprotein Inhibitor Tariquidar Is Also a Substrate and an Inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2)ACS Chemical Neuroscience, 2010
- Human P-glycoprotein is active when the two halves are clamped together in the closed conformationBiochemical and Biophysical Research Communications, 2010
- Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug BindingScience, 2009
- In silico modelling of the interaction of flavonoids with human P-glycoprotein nucleotide-binding domainEuropean Journal of Medicinal Chemistry, 2006
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- Pharmacological considerations in the modulation of multidrug resistanceEuropean Journal of Cancer, 1996
- P‐glycoprotein‐mediated transcellular transport of MDR‐reversing agentsFEBS Letters, 1993
- The mdrl gene, responsible for multidrug-resistance, codes for P-glycoproteinBiochemical and Biophysical Research Communications, 1986